Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WXTJ0262
- Development stage
- Phase 1
- Lead developer
- Cisen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
WXTJ0262 is a novel small molecule inhibitor of secretory phospholipase A2 (sPLA2) developed by Chenxin Pharmaceutical for the treatment of acute pancreatitis. The enzyme sPLA2 is a key initiator of the inflammatory cascade in pancreatitis, facilitating the hydrolysis of phospholipids into pro-inflammatory mediators such as arachidonic acid and lysophospholipids. These mediators contribute significantly to systemic inflammatory response syndrome (SIRS) and subsequent multi-organ failure, which are major complications of severe acute pancreatitis. By targeting this upstream enzyme, WXTJ0262 aims to mitigate systemic inflammation and improve clinical outcomes. The drug is formulated as an intravenous injection and is currently undergoing Phase 1 clinical evaluation in China.
Beyond the preview
Go deeper on WXTJ0262.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WXTJ0262.